Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
All articles by Anna Olechowska
Secukinumab Long-Term Reduction of Radiographic Progression in Ankylosing Spondylitis
For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.
Rituximab Effectively Treats Relapsing ANCA-Associated Vasculitis
Results from the largest prospective study of rituximab use in patients with relapsing ANCA-associated vasculitis show that 91.2% of participants achieved remission.
Femoral Stress Index is Associated with Fracture Risk in School Age Children
The FSI proved to be at least as effective in predicting fracture risk in children as femoral and total body BMD.
BMD in Menopause Improved With OSA-Related Hypoxia
The risk of bone health decline in menopausal women is decreased by intermittent hypoxia in OSA.
Hypoxia in OSA Lowers Risk of Bone Health Decline in Menopausal Women
Risk of bone health decline in menopausal women is decreased by intermittent hypoxia in OSA.
New Assessment Tool Predicts Pediatric Fracture Risk
A new bone assessment evaluates fracture risk in children.
Differences in RA Treatment Goals Between Patients and Healthcare Providers
A physician- and patient-based survey revealed differences in treatment goals, patient concerns, and more.
BMD Increased by Romosozumab in Women Transitioning From Bisphosphonates
Romosozumab could be a better option than teriparatide for patients at a high risk for fracture.
FDA Approves Duzallo for Hyperuricemia Associated With Uncontrolled Gout
The US FDA has approved a new fixed-dose and dual-mechanism treatment option for uncontrolled gout.
- Loading...
Loading...
Loading... 
Loading...